Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 23.86% is 312% above its 5-year average of -11.27%, near the high end of its 5-year range (-154.48%–23.86%).
As of the fiscal period ended Saturday, June 27, 2026. 113.41% above its 12-month average of 11.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-27): 23.86%.
RETURN ON EQUITY (ROE)
23.86%
RETURN ON EQUITY (ROE) AVG TTM
11.18%
RETURN ON EQUITY (ROE) AVG 3Y
-6.05%
RETURN ON EQUITY (ROE) AVG 5Y
-11.27%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+113.41%
CURRENT VS 3Y AVG
+494.48%
CURRENT VS 5Y AVG
+311.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 623 covered companies
CURRENT VS SECTOR MEDIAN
+159.34%
vs the sector median at left
Bioventus Inc.
Market Cap
$898.61M
Return on Equity (ROE)
23.86%
TTM Avg
11.18%
3Y Avg
-6.05%
5Y Avg
-11.27%
Market Cap
$900.79M
Return on Equity (ROE)
59.16%
TTM Avg
-57.78%
3Y Avg
-58.75%
5Y Avg
-57.09%
Market Cap
$888.21M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$914.32M
Return on Equity (ROE)
5.94%
TTM Avg
5.38%
3Y Avg
4.71%
5Y Avg
4.13%
Market Cap
$877.41M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$933.77M
Return on Equity (ROE)
-51.43%
TTM Avg
-27.77%
3Y Avg
3.43%
5Y Avg
3.43%
Market Cap
$858.40M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$938.53M
Return on Equity (ROE)
N/A
TTM Avg
30.44%
3Y Avg
30.44%
5Y Avg
30.44%
Market Cap
$948.70M
Return on Equity (ROE)
-61.58%
TTM Avg
-50.64%
3Y Avg
-52.69%
5Y Avg
41.64%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $898.61M | 23.86% | 11.18% | -6.05% | -11.27% |
| Arbutus Biopharma Corp (ABUS)vs › | $900.79M | 59.16% | -57.78% | -58.75% | -57.09% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $888.21M | -24.02% | -108.12% | -89.93% | -68.76% |
| HealthStream, Inc. (HSTM)vs › | $914.32M | 5.94% | 5.38% | 4.71% | 4.13% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $877.41M | 75.67% | 312.76% | 285.83% | 166.15% |
| CeriBell, Inc. (CBLL)vs › | $933.77M | -51.43% | -27.77% | 3.43% | 3.43% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $858.40M | -33.06% | -24.59% | -41.17% | -18.72% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $938.53M | N/A | 30.44% | 30.44% | 30.44% |
| MoonLake Immunotherapeutics (MLTX)vs › | $948.70M | -61.58% | -50.64% | -52.69% | 41.64% |
| QuidelOrtho Corporation (QDEL)vs › | $846.75M | -59.07% | -63.84% | -29.19% | -3.25% |
ROE
23.9%
ROA
8.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-27 | 23.86% |
| 2026-03-28 | 15.08% |
| 2025-12-31 | 12.35% |
| 2025-09-27 | 4.71% |
| 2025-06-28 | -0.10% |
| 2025-03-29 | -22.48% |
| 2024-12-31 | -24.03% |
| 2024-09-28 | -27.90% |
| 2024-06-29 | -29.13% |
| 2024-03-30 | -12.83% |
| 2023-12-31 | -90.00% |
| 2023-09-30 | -102.55% |
| 2023-07-01 | -154.48% |
| 2023-04-01 | -152.02% |
| 2022-12-31 | -48.80% |
| 2022-10-01 | -37.02% |
| 2022-07-02 | -4.46% |
| 2022-04-02 | -3.74% |
| 2021-12-31 | 4.22% |
| 2021-10-02 | 14.76% |
| 2021-07-03 | 22.64% |
| 2021-04-03 | 21.35% |
| 2020-12-31 | 11.54% |
